Successful new developments in cancer vaccine research, especially in exciting areas such as dendritic cell based vaccines, heat shock protein derived vaccines and T-cell responses, have immensely increased the opportunities for the design and development of new immunotherapeutics. This conference will focus on successful and novel strategies to overcome the hurdles of producing effective cancer vaccines. Topics will range from the design of novel immunotherapies, development of clinical studies and finally the challenges of commercialization.

Adjuvants
R. Rao Koganty, Ph.D, Senior Director, Research and Development and Chemistry, Biomira Inc.
Nicholas Valiante, Research Director, Chiron CorpGrayson B. Lipford, Ph.D., Director, Basic Research, Coley Pharmaceutical Group, Inc.
Kristen M. Hege, M.D., Senior Director, Clinical Research, Cell Genesys, Inc.

Immune Monitoring
Ena Wang, M.D., Staff Scientist, Immunogenetics Section, Department of Transfusion Medicine, Clinical Center, NIH
Birgit Schultes, Ph.D., Sr. Director, Research, Unither Pharmaceuticals

T-Cell Based Immunotherapy
Peter P. Lee, M.D., Assistant Professor of Medicine, Stanford University
Ron Berenson, M.D., President, CEO, Xcyte Therapies, Inc.
Laszlo Radvanyi, Ph.D., Senior Research Scientist, Immunology Platform, Aventis Pasteur
Israel Lowy, M.D., Ph.D., Director, Clinical Sciences and Infectious Diseases, Medarex, Inc.

Antigen Presenting Cells
David Avigan, M.D., Director, Hematologic Malignancy/Bone Marrow Transplant Program, Beth Israel Deaconess Medical Center 
Mary Lynne Hedley, Ph.D., Senior Vice President, R&D, ZYCOS, Inc.
Reiner Laus, M.D., Vice President of Research and Development, Dendreon Corporation
Anish S. Majumdar, Ph.D., Director of Immunology, Geron Corporation

Novel Therapeutic Approaches
Dennis Van Epps, Ph.D., Vice President, Research, CancerVax Corp.
Dr. Manfred Schuster, Project Manager, Molecular Biology, igeneon AG
Dr. Gillian Payne, Head, New TAP Research, TAP Development, ImmunoGen
Susan F. Slovin, M.D., Ph.D., Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center
Tony Mills, Vice President, Business Development, BioVex Ltd.
George C. Prendergast, Ph.D., Senior Investigator, Lankenau Institute for Medical Research

From Bench to Market
Michael Salgaller, Ph.D., Senior Associate, Toucan Capital Corp.
Antony Newton, Senior Director, Program Management, Genzyme Corporation
Neal F. Gordon, Ph.D., Senior Vice President, Manufacturing Operations, Antigenics, Inc.